Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Uncover which credit card rewards program is best for your lifestyle. Compare various options to maximize your rewards potential.
23,688 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A Nasdaq-listed Ethereum treasury firm reports an $85 million mark-to-market loss after selling ETH holdings at a dis...
Rivian priced a 75 million share secondary offering, sending its stock down around 14% and triggering a market-wide p...
A landmark federal lawsuit against OpenAI puts AI liability in the spotlight. This article explains what it means for...
Turn your Friday into a productivity booster with ten thoughtful friday reads. Each piece blends big-picture finance ...
When markets glow with optimism, Buffett’s rulebook still applies. This guide explains how to read sentiment, guard a...
A veteran lender outlines the three biggest traps in reverse mortgages as market conditions shift and seniors hold si...
When headlines scream that wall street nervous, it pays to look back. A century of S&P 500 history shows how big drop...
Greg Abel is stepping into Warren Buffett’s shoes with a plan that could redefine Berkshire Hathaway’s approach. This...
Looking to add real estate exposure for dependable income? This in-depth comparison of XLRE vs VNQ breaks down costs,...
In a volatile economy, boards are adjusting performance targets to preserve executive compensation. This piece explai...
Friday Reads offers a disciplined way to close the week. This investing digest blends macro themes, private market pe...